Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

Analytical Method Development: Use of Design of Experiments (DoE) in Method Development – V 2.0

Posted on By

Analytical Method Development: Use of Design of Experiments (DoE) in Method Development – V 2.0

SOP for Applying Design of Experiments (DoE) in Analytical Method Development


Department Analytical Method Development
SOP No. SOP/AMD/017/2025
Supersedes SOP/AMD/017/2022
Page No. Page 1 of 15
Issue Date 19/05/2025
Effective Date 20/05/2025
Review Date 19/05/2026

1. Purpose

This SOP provides a systematic approach for the application of Design of Experiments (DoE) in analytical method development. It aims

to identify critical method parameters (CMPs), understand their impact on method performance, and facilitate robust, reproducible, and scientifically justified method design in line with ICH Q8, Q9, and Q14 guidelines.

2. Scope

This SOP applies to all method development activities involving chromatographic, spectroscopic, and physicochemical analytical techniques within the Analytical Method Development (AMD) department where DoE is employed to optimize and characterize analytical methods.

3. Responsibilities

  • Analytical Scientist: Designs and executes the DoE, interprets results, and identifies MODR.
  • Statistician/Design Expert: Provides guidance on model selection, software usage, and statistical analysis.
  • Team Lead: Reviews DoE strategy, study results, and performance metrics.
  • QA: Verifies compliance with documentation and regulatory standards.
  • Head – AMD: Approves DoE-based development conclusions and MODR definition.
See also  Analytical Method Development: Selection of Mobile Phase for Chromatographic Techniques - V 2.0

4. Accountability

The Head of AMD is accountable for ensuring DoE principles are correctly applied and documented during analytical method development, enabling robust and compliant method lifecycle management.

5. Procedure

5.1 DoE Planning and Strategy

  1. Define the objective of DoE (e.g., optimization, screening, robustness).
  2. Select appropriate design:
    • Screening: Plackett-Burman, Full Factorial
    • Optimization: Central Composite Design (CCD), Box-Behnken
    • Robustness: Fractional Factorial, Taguchi
  3. Document the design plan using Annexure-1: DoE Design Summary.

5.2 Selection of Factors and Levels

  1. Identify method parameters to be studied (e.g., pH, flow rate, column temperature, mobile phase composition).
  2. Define levels (minimum, center, maximum) based on historical data or feasibility trials.
  3. Record all inputs in Annexure-2: DoE Factor Table.

5.3 Execution of Experimental Runs

  1. Perform experimental runs as per DoE matrix using validated instruments.
  2. Ensure sample prep, injection volume, and detection are consistent across runs.
  3. Monitor key responses (e.g., retention time, resolution, tailing, %RSD).
  4. Capture output in Annexure-3: DoE Experimental Log.
See also  Analytical Method Development: Analytical Control Strategy Development - V 2.0

5.4 Statistical Analysis and Model Interpretation

  1. Analyze data using statistical software (e.g., Design-Expert, Minitab, JMP).
  2. Generate response surface plots, interaction plots, and contour plots.
  3. Determine significance using ANOVA (p-value < 0.05), model R², lack of fit.
  4. Identify CMPs and estimate optimal region (MODR).
  5. Summarize findings in Annexure-4: DoE Statistical Summary.

5.5 Verification of Optimal Conditions

  1. Confirm method performance at optimal DoE-predicted settings.
  2. Conduct replicate runs and compare with predicted values.
  3. If within acceptable error range, lock the method parameters.
  4. Report verification results in Annexure-5: DoE Verification Record.

5.6 Documentation and Approval

  1. Compile all DoE-related annexures and include in Method Development Report.
  2. Obtain QA and HOD approval before proceeding to validation.
  3. Store raw data and software files in designated servers with version control.

6. Abbreviations

  • DoE: Design of Experiments
  • MODR: Method Operable Design Region
  • CMP: Critical Method Parameter
  • RSD: Relative Standard Deviation
  • Rs: Resolution
  • QA: Quality Assurance

7. Documents

  1. DoE Design Summary – Annexure-1
  2. DoE Factor Table – Annexure-2
  3. DoE Experimental Log – Annexure-3
  4. DoE Statistical Summary – Annexure-4
  5. DoE Verification Record – Annexure-5
See also  Analytical Method Development: Development of Test Procedures for API - V 2.0

8. References

  • ICH Q8(R2) – Pharmaceutical Development
  • ICH Q9 – Quality Risk Management
  • ICH Q14 – Analytical Procedure Development
  • USP General Chapter <1032> – Design and Analysis of Biological Assays

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: DoE Design Summary

DoE Type Objective Software Used Date
Central Composite Optimization of assay method Design-Expert v13 12/05/2025

Annexure-2: DoE Factor Table

Factor Low Center High Unit
Flow Rate 0.8 1.0 1.2 mL/min
pH 2.5 3.0 3.5 pH Units

Annexure-3: DoE Experimental Log

Run Flow Rate pH RT (min) Rs Tailing
1 1.0 3.0 7.8 2.1 1.1

Annexure-4: DoE Statistical Summary

Response R² Adj R² p-value Lack of Fit
Rs 0.964 0.951 <0.0001 Not Significant

Annexure-5: DoE Verification Record

Parameter Predicted Observed Deviation (%) Status
Rs 2.0 1.95 2.5% Accepted

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Added statistical annexures and verification log ICH Q14 alignment
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: BA-BE Studies: SOP for Data Entry and Source Documentation in Clinical Phase – V 2.0
Next Post: Biosimilars: SOP for Endotoxin Testing in Cell Culture – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version